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Peritoneal dialysis (PD) has been intensively oﬀered at our centre to patients (pts) with end-stage renal disease (ESRD) from
2000, and the number of PD pts was noticed to raise. We aimed to analyse the PD population from the aspect of penetration
and peritonitis rate during eleven years. Cumulative number of new RRT pts was 378 during the study period. We found high
PD penetration rate: 53% (range 32–72%). The rate of peritonitis was as high as 9.8 during ﬁrst study years, but it has declined
progressively last year being 29.1 by September 2010 and 21.7 by December 2010. Most cases of peritonitis were due to gram-
positive pathogens. We have demonstrated steady high single-centre PD penetration rate and improvement of management of
patients during last decade probably because of the result of better pts education and a continued dedication of the staﬀ.
1.Introduction
Penetration of peritoneal dialysis varies widely across the
world. It ranges from about 80% in Hong Kong and
Mexico to few percentage points in the United States
and some developing countries [1–5]. Peritoneal dialysis
appears to have some excellent properties as a ﬁrst-line
renal replacement therapy (RRT) [6]. The use of dialysis
and transplantation as complementary therapies for RRT
is well established in our country. RRT data at December
31, each year have been reported regularly to European
Dialysis and Transplantation Association Registry [7]a n d
detailed epidemiologic data available in Annual Report of
Kidney Diseases in Estonia 2009 [8]. According to reports,
the incidence and prevalence of RRT patients in our country
remains lower than that reported from the other European
countries. The incidence of RRT has a decreasing tendency
during last three years in the country being 62.7pmp at day
91 in 2008 [7]. Peritoneal dialysis (PD) was introduced to
the clinical practice already 17 years ago at our university
hospital which is the second largest centre in the country.
Since 2000, after structural changes at our centre when
nephrology division was connected with dialysis unit, we
started tointensivelyoﬀerPDtreatmenttoeverypatientwith
end-stage renal disease (ESRD) without contraindications
for PD, and the number of PD patients raised sharply. The
number of peritoneal dialysis patients have been the highest
in the country compared with other centres [8]. According
to the Annual Report PD, patients formed 47% from dialysis
prevalence patients at Tartu University Hospital at the end of
2009,whereas thepercentagewaslowerinothercentres:21%
at West-Tallinn Hospital and 44% at North-Estonia Regional
Hospital [8]. Peritonitis remains a signiﬁcant problem in
peritoneal dialysis. It is the leading cause of technique failure
in peritoneal dialysis. Therefore, we aimed to analyse our PD
population in a single-centre cohort study with respect to
penetration and peritonitis rate during last decade.
2.Materialsand Methods
The report is based on retrospective data from patient’s
records, and comparable whole country data were obtained
from Annual Report of Kidney Diseases 2009. PD pene-
tration rate was deﬁned as the percentage of new patients
on PD in relation to all new dialysis patients each year.
PD penetration rate, peritonitis rate, and microbiology
of peritoneal ﬂuid have been analysed for all pts in our
program since 2000. In conjunction with epidemiological
research study in the country, we recently expanded the2 International Journal of Nephrology
data set where individual RRT patients data together with
clinical performance indicators (CPI) at the end of each
year have been collected and analyzed beside the basic
RRT epidemiological data collection. In the current inves-
tigation, we demonstrate our single centre PD patients
CPIs that characterize anaemia, calcium phosphate, and
lipids mean patients group levels. The following biochemical
parameters (using the Hitachi 912 Analyzer until 2004
and COBAS INTEGRA 800 after 204) were studied: serum
creatinine (S-Crea, µmol/L), serum albumin (S-Alb, g/L),
C-reactive protein (CRP, mg/L), serum-ionized calcium (S-
i-Ca, mmol/l), serum total calcium (S-total Ca, mmol/L),
and serum phosphate (S-P, mmol/L). Studied lipid proﬁle
was thefollowing: serumtotal cholesterol (S-Chol,mmol/L),
serum HDL cholesterol (S-HDL chol, mmol/L), serum LDL
cholesterol (S-LDL chol, mmol/L), and serum triglyceride
(TG, mmol/L). Parathyroid hormone (PTH, pmol/L) levels
were determined by immunoanalyzer IMMULITE 2000
using chemiluminescence method. Haemoglobin (Hgb g/L)
levels were measured by photometric method. Peritonitis
w a sd e ﬁ n e da st u r b i df r e s hd i a l y s i se ﬄuent containing
polynuclear leukocyte cell count higher than 100/mm3.
Peritonitis rate was calculated as number of peritonitis
episodes per number of patients-months. For the isolation
of the organisms, blood culture media was used (BACTEC
Microbiological Culture Analyzer). Two thirds of patients
were on Baxter DUO connection system, and one third of
patients remained on Fresenius stay-safe system.
3.Resultsand Discussion
The retrospective study was carried outat the Department of
Internal Medicine of Tartu University. Cumulative number
of new RRT patients in our centre who started peritoneal
dialysis between January 2000 and December 2010 was 378.
Mean age of all incidence dialysis patients was 58.8 years in
2010 with male predominance of 57%. Demographic data
are comparable with country RRT incidence data showed in
Annual Report of Kidney Diseases 2009. According to the
Report, the mean age of incidence patients was 60.5 years,
percentageofmales58%.Diabetesisthemain causeofESRD
in new dialysis patients in Estonia [8]. Table 1 shows the
main causes of ESRD patients at our centre and comparable
data of whole country. Because of small numbers, our centre
incidence patients diabetes diagnosis percentage diﬀers from
year to year being still high every year.
Figure 1 showed the percentage of mean peritoneal
dialysis penetration rate which was 53% (range 32–72%)
in our centre during the eleven year-study period. With
these results, we demonstrate a steady peritoneal dialysis
penetration rate during long period. In our opinion, this
is because of better patients education and a continued
dedication of the staﬀ. It is important that patients and
nurses are well educated in the practice ofperitoneal dialysis.
Similarly, in other long-term studies, many centres report
higher penetration rate after essential improvement of local
skills [1–3].
Clinical and laboratory data are demonstrated in Table 2.
Results show that many of our peritoneal dialysis patients
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Figure 1:PeritonealdialysispenetrationrateattheTartuUniversity
Hospital 2000–2010.
have overweight, increased inﬂammatory status, hypoalbu-
minemia and dyslipidemia. Inﬂammation and dyslipidemia
accelerate atherosclerosis and are often present in peritoneal
dialysis patients [9, 10]. Normal range of haemoglobin
according to guidelines [11] was found in our study patients.
Arterial calciﬁcation is common in adults with chronic
kidney disease and progresses with time. On the other hand,
peritoneal calciﬁcation, one of the major complications,
can develop in peritoneal dialysis patients [12]. Therefore,
the management of secondary hyperparathyroidism and
avoidance of peritonitis should be important aims of the
treatment. We found that, although, calcium and phos-
phate levels were almost in normal range, mean PTH was
increased in our patients (Table 2). We conclude that further
improvementofthemanagementofmineralmetabolismand
secondary hyperparathyroidism as well as body composition
measurements and calciﬁcation diagnostics are needed at
our centre to avoid serious complications described by many
authors [12–15].
Peritonitis remains a major complication in patients
undergoing peritoneal dialysis and remains a major cause
of patients discontinuing peritoneal dialysis and switching
to haemodialysis. However, technique survival at year 1 has
been almost 100% at our center during last years. Because
of short period and small numbers survival, data are not
included and will be shown separately. Our study analyzed
peritonitis rate and pathogensresponsible for the peritonitis.
The incidence of peritoneal dialysis-related peritonitis was
as high as 1 episode every 9.8 months in 2004, but it has
progressively declined during the last years being 29.1 in
September 2010 and 21.7 at the end of the year (Table 3).International Journal of Nephrology 3
Table 1: Aetiology of chronic kidney disease in dialysis incident and prevalent patients at Tartu University Hospital during 2008–2010 and
in Estonia in 2009.
Incident
RRT pts at
TUH, N
(%)
Incident PD pts at TUH, N (%) Prevalent PD patients in Estonia, N (%)∗
Incident
RRT pts at
TUH, N
(%)
Prevalent PD
patients at
TUH, N (%)
Diagnosis 2010 2008 2009 2010 2008 2009 2010 2009 2009
Diabetes mellitus 4 (14) 4 (25) 9 (33) 1 (7) 6 (22) 13 (32) 7 (20) 30 24 (33)
Hypertension 5 (17) 0 (0) 5 (19) 2 (14) 4 (15) 8 (20) 5 (15) 14 18 (25)
Glomerulonephritis 5 (17) 2 (12) 3 (11) 2 (14) 5 (19) 6 (16) 6 (18) 13 6 (8)
Chronic
pyelonephritis 7 (24) 5 (32) 4 (14) 5 (37) 6 (22) 8 (20) 8 (23) 19 12 (16)
Polycystic kidney
disease 2 (7) 2 (12) 1 (4) 2 (14) 3 (11) 1 (2) 2 (6) 3 3 (4)
Other 6 (21) 3 (19) 5 (19) 2 (14) 3 (11) 4 (10) 6 (18) 21 10 (14)
∗Data from Annual Report of Kidney Diseases in Estonia 2009.
Abbreviations: TUH, Tartu University Hospital;RRT, renal replacement therapy; PD, peritoneal dialysis;N, number.
Table 2: Clinical and laboratory mean data in prevalent peritoneal
dialysis patients group at the end of year 2010.
Variables PD pts group mean SD∗ Min Max
Patients total n = 34
BMI (kg/m2) 28.8 1.1 19 43.6
Haemoglobin (g/L) 113.4 2.6 94 157
S-creatinine (µl/L) 705.5 45.6 316 1112
S-albumin (g/L) 34.3 0.9 19 42
C-reactive protein (mg/L) 9.5 1.5 1 32
S-ionized calcium (mmol/L) 1.2 0.0 1.0. 1.4
S-total calcium (mmol/L) 2.4 0.0 1.7 2.8
S-phosphate (mmol/L) 1.8 0.1 0.6 4.4
PTH (pmol/L) 52.2 10.9 1.6 197
S-total cholesterol (mmol/L) 5.7 0.2 3.0 7.8
S-HDL cholesterol (mmol/L) 1.2 0.1 0.6 1.8
S-LDL cholesterol (mmol/L) 3.9 0.2 1.9 6.2
S-triglycerides (mmol/L) 1.9 0.2 0.8 5.4
∗SD- standard deviation.
The improvement that we noticed between 2004 and
2006 may be the result of change in the connection systems
at that time. Currently, during last years, almost two thirds
of patients were on Baxter DUO connection system and one
third of patients remained on Fresenius stay-safe system.
Many centres have been reported that, over time, the
microbiology at those institutions has been changing [16].
We cannot conﬁrm this because the aetiology of peritonitis
have been similar many years. Table 4 demonstrates that
coagulase-negative staphylococcus has been the most com-
mon pathogen during 2006–2010followed by Staphylococcus
aureus.I nt w oe ﬄuentsin 2009 and three in 2010, more than
one pathogen was isolated. Thus, most cases of peritonitis
were due to Gram-positive pathogens, accounting around
35%ofallperitonitisepisodes,andGram-negative infections
were presented with a variety of diﬀerent organisms, pre-
dominantly E.coli.
Table 3: Peritonitis rate at Tartu University Hospital.
Year 2004 2006 2008 2010∗ 2010
Pts total nr 42 46 45 42 45
Pts nr at the end of the
year 29 34 27 35 34
Treatment months 354 303 409 408 500
P e r i t o n i t i s n r 3 61 91 91 4 2 3
Peritonitis rate
(episodes/nr
pts-months)
9.8 16 21.5 29.1 21.7
Peritonitis rate
(episodes/pts-year) 1.2 1.3 1.8 2.4 1.8
∗January–September 2010.
Table 4: Etiology of peritonitis at Tartu University Hospital.
Pathogen 2009-2010,
N( % )
2006-2007,
N( % )
Coagulase-negative staphylococci 21 15
Staphylococcus aureus 11 10
Streptococci 2 6
Gram-positive rod-shaped bacteriae 5 3
Enterococci 4 2
Enterobacteria 7 3
Acinetobacter baumannii 10
Pseudomonas aeruginosa 01
Yeasts 2 (3%) 0
Gram-positive organisms 43 (74%) 36 (84%)
Gram-negative organisms 8 (14%) 4 (9%)
Culture-negative peritonitis 5 (9%) 3 (7%)
Total 58 (100%) 43 (100%)
4.Conclusions
This is a ﬁrst report on long-term peritoneal dialysis expe-
r i e n c ea tas i n g l ec e n t r ei nE s t o n i a .W eh a v ed e m o n s t r a t e d4 International Journal of Nephrology
steady high single-centre peritoneal dialysis penetration rate
and declining tendency of peritonitis rate after essential
improvement of local skills.
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